FIRALIS has developed BIOPRED panel to better target inflammatory autoimmune diseases

Firalis S.A (“Firalis”), a developer of biomarker-based products and provider of biomarker services announced the release of the Biopred Immuno-Inflammatory panel, a research-use-only (RUO) product for targeted RNA profilling. The Biopred panel is now on the market, offering novel solutions in personalized medicine.